CTLA4 and diabetes mellitus: Most of the ICI-DM patients received monotherapy: 18 (78.3%) patients were treated with anti-PD-1 (5 camrelizumab, 6 pembrolizumab, 4 sintilimab, 2 tislelizumab, and 1 penpulimab), 4 (17.4%) patients were treated with anti-PD-L1 (2 durvalumab and 2 atezolizumab), and one patient received cadonilimab (PD-1/CTLA-4 bispecific antibody).